Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Hidroxicloroquina en la diabetes tipo 2 durante el embarazo

9 de noviembre de 2026 actualizado por: National University of Malaysia

Mejora en el control de la glucosa con hidroxicloroquina en la diabetes tipo 2 durante el embarazo: un ensayo controlado aleatorio

The goal of this clinical trial is to compare the use of hydroxychloroquine as an adjunct to the current treatment of pregnant women with Type 2 diabetes mellitus.

The main questions it aims to answer are:

  • Does hydroxychloroquine improve the pregnancy outcomes in women with type 2 diabetes during pregnancy?
  • Does hydroxychloroquine improve the inflammatory markers in women with type 2 diabetes during pregnancy? Participants will be randomised into the intervention and control group. The control group will be on standard treatment where as the intervention group will receive hydroxychloroquine as an adjunct of standard treatment

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

This is a randomised clinical trial comparing 2 groups i.e type 2 diabetes complicating pregnancies on standard treatment alone which comprises of oral hypoglycaemic agent with or without insulin and those with added hydroxychloroquine 200mg daily. They will be recruited within 14-20 weeks gestation. Randomisation will be done using computer software program. At recruitment, blood is withdrawn to measure glycated haemoglobin (HbA1c), full blood count, fructosamine, Interleukin-6, Interleukin-10 and Tumour Necrosis Factor-alpha. These investigations will be repeated before delivery. Patients will monitor their blood glucose using staggered 7 points which consisting of pre-meals and 1 hour post-meals using their own glucometer. The optimum fasting level is 4-5.3 mmol/l, pre meal and pre bed levels of 4-6 mmol/l and 1 hour post meal level of 4-7.8 mmol/l. All participants are followed up every 2-4 weekly whereby home blood glucose monitoring will be reviewed. Fetal growth will be monitored via serial ultrasound and charted on the fetal growth chart. Patients' care will be done by the research team which consist of obstetrician, endocrinologist and diabetic educator. All patients will have eye assessment by the ophthalmologist prior to commencement of hydroxychloroquine.

All women will be delivered at 38 weeks or earlier if there are other concomitant problems such as fetal growth restriction or poorly controlled diabetes via induction of labour. The details of the delivery for both mother and neonates will be documented. At birth, the offsprings will be seen by the neonatologist who is also in the research team. After delivery, participants will be followed up in research clinic at 6 and 12 months together with the neonate. The height and weight of the infants will be measured in centimeter. Developmental milestones will be assessed according to the developmental milestones chart of Paediatric Protocols for Malaysian Hospitals 4th Edition 2019.

Compliance to hydroxychloroquine will be assessed at each follow up, whereby an indirect method of assessing adherence of participants in the hydroxychloroquine group will be made. Each participant will be asked whether they are still taking the study medication and are required to bring the remaining medication for tablet count. Participants with remaining of more than 20% of the scheduled medications will be considered as non-compliance and treated as drop-out. Participants will also be considered as drop-out when they are lost to follow-up, withdrawal of consent, non-compliance to hydroxychloroquine or a patient becomes ill due to drug adverse effects.

Tipo de estudio

Intervencionista

Inscripción (Actual)

56

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Kuala Lumpur
      • Cheras, Kuala Lumpur, Malasia, 56000
        • Antenatal clinic, UKM Medical Centre

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

20 años a 45 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Femenino

Descripción

Inclusion Criteria:

  • Singleton
  • Pregnant women with a confirmed diagnosis of type 2 Diabetes Mellitus

Exclusion Criteria:

  • autoimmune disease such as Systemic Lupus Erythematosus or rheumatic disease
  • chronic kidney disease
  • fetal anomaly
  • women on steroid therapy
  • diabetic retinopathy
  • known thalassaemia or thalassaemia carrier

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Hydroxychloroquine group

Oral hydroxychloroquine 200mg daily will be prescribed to women in this group from recruitment (14-20 weeks) till delivery, in addition to their standard treatment

200mg daily

Otros nombres:
  • platenil
Sin intervención: Standard treatment group

Women will receive standard treatment for diabetes such as metformin and insulin.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To compare the serum glycated haemoglobin (HbA1c) between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation

Serum level of glycated haemoglobin (HbA1c) in percentage

From Day 1 up to 38 weeks of gestation
To compare the serum fructosamine between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation

Serum level of fructosamine in nanogram per milliliter

From Day 1 up to 38 weeks of gestation
To compare the serum interleukin-6 between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation

Serum level of interleukin-6 in nanogram per milliliter

From Day 1 up to 38 weeks of gestation
To compare the serum interleukin-10 between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation

Serum level of interleukin-10 in nanogram per milliliter

From Day 1 up to 38 weeks of gestation
To compare the serum tumour necrosis factor alpha between the two groups
Periodo de tiempo: From Day 1 up to 38 weeks of gestation

Serum level of tumour necrosis factor alpha in nanogram per milliliter

From Day 1 up to 38 weeks of gestation

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To compare the gestational age at delivery between the two groups
Periodo de tiempo: From recruitment up to 38 weeks of gestation

Gestational age at delivery in weeks

From recruitment up to 38 weeks of gestation
Type of labour
Periodo de tiempo: From recruitment up to 38 weeks of gestation

Onset of labour either spontaneous or induced

From recruitment up to 38 weeks of gestation
Mode of delivery
Periodo de tiempo: From recruitment up to 38 weeks of gestation

Method of patient being delivered either vaginal or caesarean section

From recruitment up to 38 weeks of gestation
Postpartum haemorrhage
Periodo de tiempo: Immediately from delivery up to 42 days post delivery

Total blood loss of more than 500 milliliters for vaginal delivery and 1000 milliliters for caesarean delivery

Immediately from delivery up to 42 days post delivery
Obstetric anal sphincter injuries
Periodo de tiempo: Immediately from delivery up to 24 hours

The number of patients who suffered third or fourth degree perineal tear

Immediately from delivery up to 24 hours
Neonatal birth weight at delivery
Periodo de tiempo: At delivery up to 24 hours

Birth weight of the neonate in grams, Neonatal birth weight of more than 90th percentile based on Fenton birth weight chart will be considered as large for gestational age or more than 4000 grams will be considered as macrosomia

At delivery up to 24 hours
Shoulder dystocia
Periodo de tiempo: At delivery up to 24 hours

Number of patient who experienced shoulder dystocia at delivery

At delivery up to 24 hours
Appearance, pulse, grimace, activity and respiration score of neonate at 5 minutes
Periodo de tiempo: At delivery up to 10 minutes after delivery

Number of neonates with Apgar score of less than 7 at birth which is bad outcome

At delivery up to 10 minutes after delivery
Number of neonates needing admission into neonatal intensive care unit
Periodo de tiempo: At delivery up to 7 days of life

Admission of neonate into neonatal intensive care unit at birth

At delivery up to 7 days of life
Height of the infant
Periodo de tiempo: At six and twelve months of age after delivery

Height or length of the infant measured in centimetres

At six and twelve months of age after delivery
Weight of the infant
Periodo de tiempo: At six and twelve months of age after delivery

Weight of the infant measured in grams

At six and twelve months of age after delivery
Hospital admission
Periodo de tiempo: From day 7 of life up to twelve months of age

Numbers of infants required hospital admission

From day 7 of life up to twelve months of age

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Rahana Abd Rahman, UKM

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

24 de marzo de 2024

Finalización primaria (Actual)

1 de junio de 2026

Finalización del estudio (Actual)

1 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

23 de enero de 2024

Primero enviado que cumplió con los criterios de control de calidad

12 de marzo de 2024

Publicado por primera vez (Actual)

20 de marzo de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

9 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir